Any alcohol use in NAFLD patients is associated with significant changes to the intestinal virome.
Journal
Hepatology (Baltimore, Md.)
ISSN: 1527-3350
Titre abrégé: Hepatology
Pays: United States
ID NLM: 8302946
Informations de publication
Date de publication:
01 06 2023
01 06 2023
Historique:
received:
28
09
2022
accepted:
23
11
2022
pmc-release:
01
06
2024
medline:
18
5
2023
pubmed:
12
1
2023
entrez:
11
1
2023
Statut:
ppublish
Résumé
The prevalence of alcohol use disorder (AUD) and metabolic dysfunction-associated fatty liver disease (MAFLD) are increasing worldwide, leading to the increasing likelihood of both etiologies contributing to a patient's liver disease. However, the effects of modest alcohol use in NAFLD are controversial and more studies are needed. We compared the intestinal viromes of patients with AUD and NAFLD in order to evaluate the effect of alcohol consumption on the intestinal viromes of NAFLD patients by extracting virus-like particles and performing metagenomic sequencing. Viral nucleic acids were extracted from fecal samples and subjected to metagenomic sequencing. We demonstrate significant differences in the intestinal viromes of NAFLD and AUD patients, and that alcohol use in NAFLD patients reclassified to MAFLD accounted for significant differences in the intestinal viromes. The relative abundance of several Lactococcus phages was more similar between AUD patients and alcohol-consuming MAFLD patients than non-alcohol-consuming MAFLD patients and control subjects, and multivariate modeling using the most discriminating Lactococcus phages could better predict alcohol use in the MAFLD population than the alcohol-associated liver disease/NAFLD Index. Significant differences in the viral composition and diversity were also seen between MAFLD patients with low and moderate alcohol consumption compared with no alcohol consumption. The intestinal virome of MAFLD patients who consume low to moderate amounts of alcohol are significantly different from those who do not, and many features of the intestinal virome of alcohol-consuming MAFLD patients resemble that of AUD patients.
Sections du résumé
BACKGROUND AND AIMS
The prevalence of alcohol use disorder (AUD) and metabolic dysfunction-associated fatty liver disease (MAFLD) are increasing worldwide, leading to the increasing likelihood of both etiologies contributing to a patient's liver disease. However, the effects of modest alcohol use in NAFLD are controversial and more studies are needed. We compared the intestinal viromes of patients with AUD and NAFLD in order to evaluate the effect of alcohol consumption on the intestinal viromes of NAFLD patients by extracting virus-like particles and performing metagenomic sequencing.
APPROACH AND RESULTS
Viral nucleic acids were extracted from fecal samples and subjected to metagenomic sequencing. We demonstrate significant differences in the intestinal viromes of NAFLD and AUD patients, and that alcohol use in NAFLD patients reclassified to MAFLD accounted for significant differences in the intestinal viromes. The relative abundance of several Lactococcus phages was more similar between AUD patients and alcohol-consuming MAFLD patients than non-alcohol-consuming MAFLD patients and control subjects, and multivariate modeling using the most discriminating Lactococcus phages could better predict alcohol use in the MAFLD population than the alcohol-associated liver disease/NAFLD Index. Significant differences in the viral composition and diversity were also seen between MAFLD patients with low and moderate alcohol consumption compared with no alcohol consumption.
CONCLUSIONS
The intestinal virome of MAFLD patients who consume low to moderate amounts of alcohol are significantly different from those who do not, and many features of the intestinal virome of alcohol-consuming MAFLD patients resemble that of AUD patients.
Identifiants
pubmed: 36631002
doi: 10.1097/HEP.0000000000000238
pii: 01515467-990000000-00266
pmc: PMC10192041
mid: NIHMS1883886
doi:
Substances chimiques
Ethanol
3K9958V90M
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2073-2083Subventions
Organisme : BLRD VA
ID : I01 BX004594
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK120515
Pays : United States
Organisme : NIDDK NIH HHS
ID : T32 DK007202
Pays : United States
Informations de copyright
Copyright © 2023 American Association for the Study of Liver Diseases.
Références
Microbiome. 2017 Oct 17;5(1):141
pubmed: 29041989
Hepatol Commun. 2022 Aug;6(8):2058-2069
pubmed: 35368152
J Hepatol. 2022 Oct;77(4):918-930
pubmed: 35605744
Gastroenterology. 2020 Nov;159(5):1839-1852
pubmed: 32652145
Gut Microbes. 2020 Nov 9;12(1):1785251
pubmed: 32684075
J Hepatol. 2020 Jul;73(1):202-209
pubmed: 32278004
J Clin Med. 2022 Feb 08;11(3):
pubmed: 35160340
Scand J Gastroenterol. 2017 Feb;52(2):159-165
pubmed: 27650916
J Hepatol. 2012 Aug;57(2):384-91
pubmed: 22521357
Hepatology. 2020 Dec;72(6):2182-2196
pubmed: 32654263
Gastroenterology. 2006 Oct;131(4):1057-63
pubmed: 17030176
Gut Microbes. 2020 Nov 9;12(1):1782157
pubmed: 32588725
Elife. 2021 May 04;10:
pubmed: 33944776
Methods Mol Biol. 2018;1838:85-95
pubmed: 30128991
Liver Int. 2020 Jun;40(6):1356-1365
pubmed: 32243703
Clin Gastroenterol Hepatol. 2018 Sep;16(9):1511-1520.e5
pubmed: 29378307
Curr Gastroenterol Rep. 2014 Feb;16(2):372
pubmed: 24452634
Bioinformatics. 2018 Apr 1;34(7):1235-1237
pubmed: 29194469
J Hepatol. 2017 May;66(5):1022-1030
pubmed: 28039099
Genome Biol. 2011 Jun 24;12(6):R60
pubmed: 21702898
Gut. 2014 Mar;63(3):530-2
pubmed: 24026352
Front Physiol. 2021 Jul 19;12:699253
pubmed: 34349667
Liver Int. 2020 Apr;40(4):860-865
pubmed: 31943701
Ann Gastroenterol. 2021 Jul-Aug;34(4):568-574
pubmed: 34276197